Outcome in schizophrenia: Beyond symptom reduction

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 3, 1999, Pages 3-8

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; ARTICLE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MENTAL HEALTH CARE; MORTALITY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMBINED MODALITY THERAPY; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032970757     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990;14:522-525
2. Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophienia. Br J Psychiatry 1987;150:345-354
3. Health Care Reform for Americans With Severe Mental Illnesses: Report of the National Advisory Mental Health Council. Am J Psychiatry 1993; 150:1447-1465
4. Chang CF, Kiser LJ, Bailey JE, et al. Tennessee's failed managed care program for mental health and substance abuse services. JAMA 1998;279: 864-869
5. Oss M. Evaluation of Proposed 1998 TennCare Partners Behavioral Health Rate-Setting Methodology. Nashville: Tennessee Association of Mental Health Organizations; 1998
6. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Cur Med Res Opin 14;1997:1-20
7. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
8. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990;81:231-235
9. Meltzer HY, Cola F, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
10. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-131
11. Meltzer HY, McGurk SR. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull. In press
12. Meltzer HY, Thompson PA, Lee MA. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996;14(3, suppl):27S-33S
13. Fujii DE, Ahmed I Jokumsen M, et al. Effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997;9:240-245
14. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
15. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804
16. Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptics. Eur Neuropsychopharmacol 1996;6(suppl 2):13-20
17. Franz M, Lis S, Pluddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-425
18. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41-49
19. Aronson SM. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139-147
20. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
21. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
22. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997;58(suppl 10):18-21
23. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
24. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40